Lifeboat Foundation

More news on senolytics.

Efforts to build rejuvenation therapies that work by selectively destroying senescent cells are very much in the news of late. One class of senolytic drug candidates works by inducing apoptosis, a form of programmed cell death, via reduced levels of Bcl-2 family proteins, such as Bcl-2 itself, Bcl-xL, and Bcl-W, all of which normally act to suppress apoptosis. Senescent cells are inclined towards apoptosis already, so a modest nudge in that direction can destroy a fair proportion of these unwanted cells without causing harm to healthy cells. These apoptosis-related proteins have numerous other roles as well, however, since evolution is very much in favor of reusing the tools to hand. For example, Bcl-xL is also involved in mitochondrial damage protection, the immune response, cellular respiration and DNA repair: quite the portfolio, and all items that are connected to aging in one way or another. I noted an open access paper today that muddies the water considerably on the topic of Bcl-xL, as it shows that more Bcl-xL rather than less (a) reduces incidence of cellular senescence in tissue cultures, (b) extends life in nematode worms, and © is found in human centenarians, but not younger individuals.

Ordinary somatic cells, the vast majority of the cells in the body, become senescent when they reach the Hayflick limit at the end of their replicative life span, or in response to damage, or a toxic local environment, or as a part of the wound healing process. Senescent cells cease dividing, and most either self-destruct or are destroyed by the immune system soon afterwards. This behavior has evolved because it suppresses cancer incidence, at least initially, by removing those cells most at risk. Unfortunately not all are destroyed, and those that linger cause harm to surrounding tissues via a potent mix of inflammatory signals known as the senescence-associated secretory phenotype (SASP). Given enough senescence cells, as few as 1% or less of all the cells in an organ, significant dysfunction and inflammation is the result, contributing to the development and progression of age-related disease.

Continue reading “Complicating the Picture for Aging, Cellular Senescence, and Bcl-xL” »

This was a huge step forward for rejuvenation biotechnology earlier this year. Synthetic glucosepane can now be created on demand in the lab thanks to SENS research foundation and the work at Yale it is funding. Glucosepane is thought to be involved in hypertension and diabetes and so this research has important implications for these diseases as well as aging in general.

At Yale, we’re funding Dr. Spiegel’s essential work to characterise the molecular crosslink glucosepane, which stiffens blood vessels and skin as we age.

George Church on the frontline of genetics once again!

In Brief:

• A new visual implant from SecondSight may help restore useful sight in more than 6 million additional people who aren’t candidates for the company’s previous implant model.
• Recently, there are more options being developed to restore both hearing and sight in affected patients, such technology has the potential to improve the quality of life of countless people.

Who would have thought that roaches, that’s right, C-O-C-K-R-O-A-C-H-E–S, could actually do something good for humanity? Well, it seems that they are helping out quite a lot.

Bar-Ilan University scientists, together with the Interdisciplinary Center in Israel, designed injectable nanobots, and they are testing them on these little critters. Remarkably, the technology controls the release of drugs that are needed for the brain using the brain itself. That’s right, using only brain power!

And down the road, this extra mind boost could be a lifesaver for many. The work was published in the journal PLOS ONE.

Continue reading “Scientists Made Nanorobots That Can Release Drugs in The Body Using Mind-Control” »

“Cancer is a disease of ageing,” Lin, geneticist and president of the Rare Genomics Institute, told the audience at WIRED2016. The World Health Organisation estimates there are about 14 million new cases of cancer every year, and predicts that figure will double by 2050. Currently, eight million people are killed every year by the disease.

By combining early intervention with an understanding of cancer genomics, however, mankind could be on the cusp of fighting cancer effectively and at scale. “We are at the intersection of three of the most exciting revolutions in cancer therapy,” Lin said.

The SENS Research Foundation launched the new Alliance Program in January and important step towards the kind of future we would all like to see.

SRF Director of Alliances David Brindley returned to the stage to introduce our new Alliance Program, launched in January 2016 with an initial $500,000 grant from SRF and building on David’s experience managing the successful CASMI Translational Stem Cell Consortium. Although SENS research to date has produced very promising pre-clinical results, the novelty and disruptiveness of the platform means that many of the therapies we propose currently lack a clear path to the market. The Alliance Program is designed to streamline that process in partnership with existing public and private entities worldwide, particularly by funding PhD and post-doctoral fellowships addressing specific translational needs.

As atoms in our bodies were made in stars millions of years ago, it’s been common to propose that we are, in fact, made of stars. Now comes news of another mind-blowing cosmic relationship as physicists conclude that human cells and neutron stars share structural similarities, which look like multi-story parking garages.

Neutron stars are quite strange space objects. They come to life as a result of supernova explosions of massive stars and are incredibly dense. While they are the smallest stars, they can pack as much mass as two Suns into a star with the radius of just 10 kilometers.

Continue reading “Humans and Supernova-Born Neutron Stars Have Similar Structures, Discover Scientists” »

Biologists at Caltech have developed a new system for visualizing connections between individual cells in fly brains. The finding may ultimately lead to “wiring diagrams” of fly and other animal brains, which would help researchers understand how neurons are connected.

“To understand how the brain works we need to know how neurons are wired to each other,” says Carlos Lois, research professor in the Division of Biology and Biological Engineering at Caltech and principal investigator of the new research, which appears in the November issue of the journal Development. “This is similar to understanding how a computer works by looking at how transistors are connected.”

Animals are made up of different types of specialized cells. In order for an animal to function, the cells have to be able to communicate with each other. For example, neurons directly communicate with muscle cells so that an animal can move. In diseases such as cancer, this communication process can go awry: when tumors metastasize, they no longer “listen” to neighboring cells that tell them not to grow. Instead, the cancer cells grow uncontrollably and migrate to other parts of the body.

Continue reading “The wiring of fly brains—mapping cell-to-cell connections” »